** Shares of drug developer FibroGen FGEN.O jump 79.7% to $1.01 premarket
** FGEN says it is selling its China unit to AstraZeneca AZN.L for about $160 mln
** Deal includes an enterprise value of $85 mln plus FibroGen net cash held in China at closing, estimated at about $75 million
** Deal expected to close by mid-2025
** AZN will obtain all rights to anemia drug, roxadustat, in China, while FibroGen retains rights to roxadustat in the U.S. and other markets
** FGEN plans to have an FDA meeting in Q2 2025 to determine next steps for roxadustat development in the U.S.
** Deal will extend FGEN's cash runway into 2027, co says
** FGEN fell ~36% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。